Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (369) clinical trials

People with multiple myeloma are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy …

Phase

Phase 1 Study Of PF-06863135 A BCMA- CD3 Bispecific Ab As A Single Agent And In Combination With Either PF-06801591 Or Lenalidomide In Relapse/ Refractory Multiple Myeloma

Study C1071001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic study of PF-06863135 in adult patients with advanced multiple myeloma who have relapsed from or are refractory to standard therapy. This two part study will assess the safety and tolerability of …

Phase

Immuno-Oncology Drugs Elotuzumab Anti-LAG-3 and Anti-TIGIT

This study will enroll 104 patients to one of three treatment arms. The study is open to patients relapsing with refractory Multiple Myeloma who have: received 3 prior lines of therapy exposed to each of these 3 drug classes: IMiD proteasome inhibitors, and anti-CD38 monoclonal antibody relapsed and refractory are …

Phase

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have two parts. In the first part, participants get SEA-BCMA by itself. This part of the study will find out how …

Phase

Umbilical Cord Blood-Derived Natural Killer Cells Elotuzumab Lenalidomide and High Dose Melphalan Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

PRIMARY OBJECTIVES: I. To find the maximum tolerated dose (MTD) of umbilical cord blood (UCB)-derived natural killer (NK) cells. II. To determine efficacy by the percent of patients achieving very good partial remission (VGPR) + complete remission (CR) at 3 months post-transplant. III. To assess the minimal residual disease rate …

Phase

An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have MM. This study will look at the effectiveness and safety in participants who take ixazomib in addition to lenalidomide and dexamethasone. The study will enroll approximately 160 participants. Participants will initially …

Phase

PROactive Evaluation of Function to Avoid CardioToxicity

This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.

Phase

An Open-label Dose Escalation Study in Japanese Subjects With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

GSK2857916 is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate (ADC) which binds specifically to B cell maturation antigen (BCMA) expressed on tumor cells of all subjects with multiple myeloma (MM). This is a Phase 1, open label, dose escalation study to …

Phase